Guillain barre syndrome following Pfizer-BioNTech (BNT162b2) vaccination: a case report

Annals of Medicine & Surgery Pub Date : 2024-05-20 DOI:10.1097/ms9.0000000000002197

A. Chaudhary, Shrekshya Khadka, Aliza Dulal, Rojeena Adhikari, Sushant Bhardwaj, Abhishek Pandey, Ashlesha Chaudhary, S. Bhusal, Smriti Acharya

{"title":"Guillain barre syndrome following Pfizer-BioNTech (BNT162b2) vaccination: a case report","authors":"A. Chaudhary, Shrekshya Khadka, Aliza Dulal, Rojeena Adhikari, Sushant Bhardwaj, Abhishek Pandey, Ashlesha Chaudhary, S. Bhusal, Smriti Acharya","doi":"10.1097/ms9.0000000000002197","DOIUrl":null,"url":null,"abstract":"\n \n Pfizer-BioNTech (BNT162b2) is one of the mRNA vaccines currently approved by the World Health Organization (WHO) and the Food and Drug Administration (FDA) against COVID-19.\n \n \n \n Here, we report a case of an 8-year-old female with Guillain-Barré syndrome following the 2nd dose of Pfizer-BioNTech (BNT162b2) vaccination requiring respiratory support who was managed with intravenous immunoglobulin.\n \n \n \n There have been reports of Guillain-Barré syndrome following the Pfizer-BioNTech vaccination. In our case, as the symptoms of GBS occurred right after the vaccination, there could be an association, and this report can add to the existing literature and raise awareness about the possible adverse effects of the Pfizer-BioNTech vaccination.\n \n \n \n Although most adverse effects following Pfizer-BioNTech (BNT162b2) vaccination have been reported as non-serious, clinicians must be aware of serious adverse effects that, though rare, can follow the administration of Pfizer-BioNTech vaccination and require prompt recognition and management.\n","PeriodicalId":373451,"journal":{"name":"Annals of Medicine & Surgery","volume":"21 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medicine & Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ms9.0000000000002197","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Pfizer-BioNTech (BNT162b2) is one of the mRNA vaccines currently approved by the World Health Organization (WHO) and the Food and Drug Administration (FDA) against COVID-19. Here, we report a case of an 8-year-old female with Guillain-Barré syndrome following the 2nd dose of Pfizer-BioNTech (BNT162b2) vaccination requiring respiratory support who was managed with intravenous immunoglobulin. There have been reports of Guillain-Barré syndrome following the Pfizer-BioNTech vaccination. In our case, as the symptoms of GBS occurred right after the vaccination, there could be an association, and this report can add to the existing literature and raise awareness about the possible adverse effects of the Pfizer-BioNTech vaccination. Although most adverse effects following Pfizer-BioNTech (BNT162b2) vaccination have been reported as non-serious, clinicians must be aware of serious adverse effects that, though rare, can follow the administration of Pfizer-BioNTech vaccination and require prompt recognition and management.

查看原文本刊更多论文

辉瑞-生物技术公司（BNT162b2）疫苗接种后的格林巴利综合征：病例报告

辉瑞生物技术（BNT162b2）是目前世界卫生组织（WHO）和美国食品药品管理局（FDA）批准的针对 COVID-19 的 mRNA 疫苗之一。在此，我们报告了一例 8 岁女性在接种第二剂辉瑞-生物纳米技术（BNT162b2）疫苗后出现吉兰-巴雷综合征的病例，患者需要呼吸支持，并接受了静脉注射免疫球蛋白的治疗。曾有关于接种辉瑞生物技术疫苗后出现吉兰-巴雷综合征的报道。在我们的病例中，由于 GBS 症状是在接种疫苗后立即出现的，因此可能存在关联，本报告可以补充现有文献，提高人们对辉瑞生物疫苗接种可能产生的不良反应的认识。尽管大多数关于辉瑞-生物技术（BNT162b2）疫苗接种后不良反应的报道都不严重，但临床医生必须注意辉瑞-生物技术疫苗接种后可能出现的严重不良反应，尽管这些不良反应很少见，但需要及时识别和处理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Medicine & Surgery

自引率

0.00%

发文量